Literature DB >> 29682541

Madelung's Disease: Lipectomy or Liposuction?

Chun-Ye Chen1, Qing-Qing Fang1,2, Xiao-Feng Wang1,2, Min-Xia Zhang1, Wan-Yi Zhao1,2, Bang-Hui Shi1, Li-Hong Wu1, Li-Yun Zhang1, Wei-Qiang Tan1,2.   

Abstract

BACKGROUND: Madelung's disease is a rare lipid metabolic disorder characterized by diffuse, uncapsulated lipomas in the neck, shoulder, and other areas. It mainly affects middle-aged men and is related to alcohol abuse, and the cause is not clear. Surgical treatments include lipectomy and liposuction.
METHODS: This systematic review analyzed the treatment of Madelung's disease described in 52 articles including complete patient details, published between 2000 and 2015, and retrieved from the Web of Science, PubMed, Medline, and Embase.
RESULTS: Lipectomy was performed in most cases and achieved more complete removal and better control of iatrogenic lesions of nearby structures than liposuction. Liposuction achieved good cosmetic results and is simpler and less invasive than lipectomy, but clinical experience is limited.
CONCLUSIONS: Both lipectomy and liposuction have advantages and drawbacks. Surgeons should base the choice of optimal treatment on patient characteristics. Novel surgical techniques and etiologically targeted treatments hold promise as future therapies.

Entities:  

Mesh:

Year:  2018        PMID: 29682541      PMCID: PMC5840946          DOI: 10.1155/2018/3975974

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Madelung's disease, multiple symmetrical lipomatosis, or benign symmetric lipomatosis is a rare disorder of adipose metabolism that was first reported in 1846 by Benjamin Brodie. It presents with multiple, symmetrical, nonencapsulated fatty masses in the maxillofacial region, neck, shoulder, trunk, limbs, and other areas. In most patients, neck involvement results in a specific sign called Madelung's or horse collar [1, 2]. Madelung's disease is more common in middle-aged men of Mediterranean origin and is related to alcohol abuse. However, cases have been reported in women, patients in south east countries, and in nondrinkers [1-3]. The disease is not painful; most but not all cases have a slow clinical course [1], and malignant transformation is infrequent [1, 2]. Transformation to intramyxoid sarcoma after a 6-year follow-up was reported by Tizian; a case of liposarcoma transformation was reported by Sia et al. [3-5]. Cosmetic deformity and compression symptoms such as dyspnea and dysphagia are indications for treatment. Comorbidities such as liver cirrhosis, nephropathy, neuropathy, and metabolic disorders have been reported [1-3], but no causal relationships between those disorders and Madelung's disease have been established [6]. Two types of Madelung's disease can be distinguished by their clinical characteristics [1, 2, 6]. Type I occurs most often in men, generally as a symmetrical distribution of superficial fatty masses with a “pseudoathletic” appearance, which are likely to cause compression symptoms. Type II can occur in both men and women, with a presentation similar to generalized obesity. The classification is not very exacting. The etiology of Madelung's disease has not been established, but recent evidence has implicated mitochondrial dysfunction resulting from mutations of mitochondrial DNA [1, 2, 7] and changes in enzyme and membrane receptor activity that reduce adrenergic-mediated lipolysis. Alcohol consumption might serve as a predisposing or aggravating factor [6]. The diagnosis can made by clinical features and imaging studies [2]. Computed tomography, ultrasonography, and magnetic resonance imaging determine the adhesion to, size, location, and compression of adjacent tissue. Imaging thus helps with the diagnosis, differential diagnosis, and preoperative assessment [2, 8]. The use of magnetic resonance imaging for assessment and preoperative planning has been recently reviewed in a case report by Sharma et al. [9]. Histologically, the adipocytes present in the fatty masses in Madelung's disease are smaller, and the content of fibrous and vascular tissues is greater than normal [6]. There is also a loss of large myelinated cells, but without the demyelination or axonal degeneration induced by chronic alcohol ingestion [2]. At least one report found that the triglyceride content of fat cells was affected [6]. This systematic review summarizes the current treatment of Madelung's disease and the choice of treatment in different clinical contexts.

2. Methods

2.1. Literature Search

This systematic review followed the PRISMA guidelines. The Web of Science, PubMed, Medline, and Embase were searched for case reports of Madelung's disease published from 2000 to 2015. The search terms were “Madelung disease,” “Madelung syndrome,” “multiple symmetrical lipomatosis,” and “benign symmetric lipomatosis.” Duplicate publications, meeting abstracts, treatment guidelines, recommendations, literature reviews without case reports, experimental animal model studies, etiologic investigations, and cases reports without clear clinical data including patient age, sex, symptoms, and treatment were excluded.

2.2. Analysis

A total of 52 studies published from 2000 to 2015 included complete patient characteristics and treatment descriptions and were selected for review [1–3, 8, 10–57]. The studies are listed in Table 1. For ease of understanding, the clinical characteristics and treatment methods of these patients with Madelung's disease are summarized in Table 2.
Table 1

41 literature sources of Madelung's disease from 2000 to 2015 with complete materials of treatment.

Published dateAuthorsCasesMale : femaleAge or average ageTreatmentAfter treatment
LipectomyLiposuctionOtherRelapse (follow-up times)No relapse (follow-up times)Unknown
2015Azuma et al.11 : 074100001
 2015aAndou et al.11 : 051001 (intralipotherapy)01 (4 years)0
2015Kang et al.11 : 064100001
2015Zielińska-Kaźmierska et al.11 : 046100001
 2015bOzderya et al.11 : 029001 (medical therapy)01 (3 years)0
2014Jang et al.11 : 066100001
2014Celentano et al.11 : 05110001 (36 months)0
2014Z. Pinnella and J. Pinnella11 : 05210001 (30 months)0
 2014cScevola et al.22 : 047002 (intralipotherapy)002
2014Orasmo et al.11 : 048100001
 2014dHundeshagen et al.22 : 058.520002 (8–13 months)0
2014Tai et al.11 : 0541001 (2 years)00
2014Shibasaki et al.11 : 047100001
 2014eAgostini et al.11 : 06211001 (1 year)0
2013Nikolić et al.11 : 0511001 (3 years)00
2013Kang and Kim10 : 176100001
2013Ardeleanu et al.11 : 055100001
2013Klobucnikova et al.22 : 058200002
 2012fBorriello et al.10 : 1591001 (malignant)00
2012Lee et al.11 : 05010001 (10 months)0
2012Sia et al.11 : 04510001 (1 week)0
2012Subash et al.11 : 049100001
2012Friedl et al.10 : 155001 (medical therapy)001
 2012bTufan et al.11 : 056001 (medical therapy)001
2012Mevio et al.33 : 059.3300003
2012Di Candia and Cormack11 : 034100001
2011Albu11 : 05910001 (2 years)0
2011Lee et al.11 : 07110001 (2.4 years)0
2011Ampollini and Carbognani11 : 045001 (medical therapy)001
2010Milisavljevic et al.11 : 05810001 (1 year)0
2009Juric and Carapina11 : 069001 (medical therapy)001
2009Alameda et al.11 : 055100001
2009Tekin and Ogetman11 : 026100001
2009Lee et al.11 : 064100001
2008Verna et al.42 : 255.25310004
 2008eTan and Ergen10 : 12011001 (22 months)0
2007Bulum et al.11 : 051100001
2007Ali and Kishore11 : 05310001 (6 months)0
2006Lopez-Ceres et al.10 : 157100001
 2006eConroy11 : 051110001
2005Colella et al.11 : 044100001
2004Uglešić et al.11 : 05310001 (5 months)0
2004González-García et al.22 : 051.520002 (1 and 10 years)0
 2003eConstantinidis et al.1110 : 147111102 (1 and 1.5 years)90
2003Verhelle et al.54 : 152.55001 (10–48 years)40
2002Guastella et al.21 : 159.520001 (18 months)1
2001Ujpaál et al.3129 : 241.53100011 (17.1 years)20
2001Faga et al.11 : 0510101 (1 year)00
 2001eNielsen et al.10 : 150110001
2001Fischer et al.11 : 043001 (intratumoral injection)001
 2000ePayne11 : 06911001 (1 year)0
2000Vargas-Díez et al.11 : 05910001 (6 months)0

Sum10693 : 139518974455

Average52.9

Percentage0.89620.16980.0849

A total of 41 studies published from 2005 to 2015 included complete patient characteristics and treatment descriptions and were selected for review [1–3, 8, 10–57]. aThis patient had a relapse 4 years after treatment, then surgical procedure was performed, and there was no recurrence of the lipomatosis after a 32-month follow-up. bThe lipomatosis of 2 patients remained unchanged in 4-month to 3-year follow-up. cThese 2 patients both had successful previous surgical excision. dThis patient had failed liposuction before. ePatients in these cases were submitted to liposuction combined with lipectomy. fMalignant happened in this case.

Table 2

Summary of the clinic data of published cases of Madelung disease.

AgeMiddle age

SexAppearing mostly in male

Most frequent locationsNeck and face

Most frequent comorbiditiesNephropathy, hepatopathy, and metabolic abnormalities

Treatment
 Surgical method (most)Lipectomy (most) and liposuction
 Medical procedureIntralipotherapy and medical therapy
 New techniquesCombined lipectomy and liposuction, ultrasound-assisted liposuction (UAL), tunneling technique, cervical dissection technique, powered-assisted liposuction (PAL), rhytidectomy approach, special incisions (a small submental incision and slightly modified rhytidectomy incisions, posterior neck incision, T shaped incision)

The main problem after treatmentRelapse, especially after liposuction

A simple summary of the clinic date of the 106 published cases of Madelung's disease.

3. Results

3.1. Characteristics of Reported Cases

The average age of the 106 reported cases from the 52 studies (Table 1) was 52.9 years, and the male-to-female ratio was 93 : 13. The majority of masses were located on the neck and face, but the trunk and limbs are also common sites. Lipomas were rarely reported around the eye or on the tongue, throat, breast, pubis, and testis. The most frequent comorbidities were nephropathy, hepatopathy, and metabolic abnormalities. Klinefelter syndrome, acquired immunodeficiency syndrome, and sexual dysfunction were rarely reported comorbidities. Surgery was the most frequent treatment, 8.49% of the patients were treated medically. Intralipotherapy was used in three patients (2.86%) described in two reports. One intralipotherapy patient (Table 1a) had a recurrence 4 years after treatment. It was treated surgically without a second recurrence at 32 months of follow-up [10]. The other two patients (Table 1c) had both experienced a successful prior surgical excision [18]. And this study showed that intralipotherapy achieved a 2.5% reduction in average size and had a 33% recurrence rate [18]. Medical therapy was described in five reports. Lipomatosis remained unchanged in two of those patients (Table 1b) after 4 months to 3 years of follow-up [14, 32]. The other three studies did not report whether any relapses had occurred. Ninety-five patients (89.62%) were treated surgically by lipectomy, and 79 of them were treated by lipectomy only. Four of those 79 patients experienced relapses, one experienced malignant transformation (Table 1f) [28], and 30 patients with reported follow-up did not experience a relapse. Whether or not relapse occurred was not reported for 24 patients. One surgery patient (Table 1d) had failed liposuction [20]. Only 18 patients (16.98%) were treated by liposuction, and 2 of them were treated by liposuction only: one experienced relapse after 1 year of follow-up [53], and the other case was not mentioned. Sixteen of the 18 patients experienced procedures that were combined with lipectomy (Table 1e) [23, 43, 47, 54, 56]. Two of the 16 patients experienced relapse after 1 and 1.5 years of follow-up [49].

3.2. Synthesis of Results

Table 2 summarizes the clinical characteristics of the published cases of Madelung's disease. Most patients were middle-aged men, and the most frequent locations were on the neck and face. The most frequent comorbidities were nephropathy, hepatopathy, and metabolic abnormalities. Most patients were treated surgically by lipectomy and a few by liposuction. Medical procedures were seldom used and included mainly intralipotherapy. Novel techniques included combined lipectomy and liposuction, ultrasound-assisted liposuction, tunneling techniques, cervical dissection techniques, powered-assisted liposuction, and a rhytidectomy approach. The main treatment-related problem was relapse, especially following liposuction.

4. Discussion

Treatment for Madelung's disease included both surgical and nonsurgical procedures. Surgical treatment was the most frequent treatment and included lipectomy and liposuction.

4.1. Nonsurgical Treatment

Some reports recommended intralipotherapy as a noninvasive treatment of Madelung's disease, in which the mass was injected with phosphatidylcholine/deoxycholate. Scevola et al. confirmed the efficacy of intralipotherapy after long-term assessment [18]. Intralipotherapy mainly limits the growth of adipose masses and is not highly effective in reducing their volume. If surgical dissection is planned, then surgeons should be aware of the potential for adhesions in patients who were previously treated with injection lipolysis [10]. Abstinence from alcohol may slow the enlargement of adipose masses but cannot reverse the disease. The risk of recurrence is decreased by abstaining from alcohol after surgery. Other lifestyle modifications that improve blood glucose and lipid control in patients with comorbidities may prevent growth of adipose masses but do not reduce their size [3]. Dietary management does not help [2]. Other therapeutic methods such as injecting lesions with enoxaparin and β2 agonists [2] may be effective, but their curative effects have not been clearly demonstrated.

4.2. Lipectomy

Lipectomy and liposuction are the most effective surgical options, but because the etiology of Madelung's disease is not clear, they are seen as palliative surgery [3]. Lipectomy was performed in most reported cases, allowing for satisfactory exposure and allowing for complete removal with good control of iatrogenic lesions of nearby structures, especially vessels and nerves. Although direct visualization reduces the risk of injury, lipectomy is not technically easy because the lipomas are nonencapsulated with wide infiltration of surrounding tissue [2, 58]. During surgery, the pathological hyperplastic lipoma is difficult to distinguish from subcutaneous fat and other healthy tissues [3]. Lipectomy has disadvantages of an increased rate of surgical complications including infection, hemorrhage, hematoma, lymphatic fistula, and pathologic scarring [1, 2, 8, 58]. Although it is an open approach, debulking surgery has been recommended as allowing for a better cosmetic result than lipectomy, with the exception of scar formation [6]. Most reports recommend a single transverse incision rather than multiple direct incisions to remove Madelung's collar [2].

4.3. Liposuction

Liposuction has gained in popularity because it is less traumatic and has better cosmetic outcomes than surgery. However, because it has not been widely used, there is little clinical experience with liposuction in Madelung's disease patients. The advantages of liposuction include simplicity, minimal invasiveness, and low morbidity; it has been an adjunct therapy in many cases. In addition, its dense and fibrous composition make it difficult to aspirate the fatty tissue in the conventional way [1, 2, 8], posing a problem for surgeons during liposuction. The nature of the adipose masses also decreases the reliability of preoperative assessment of possible liposuction failure. There are no histological assessments, like the extent of fibroplasia, that allow avoiding the difficulties of liposuction [8]. It is difficult to achieve complete removal either by liposuction or lipectomy because the lipomas are nonencapsulated, making recurrence nearly unavoidable. Finally lipectomy and liposuction are not simple because growth of the fatty masses may proceed in more than one direction and involve several structures [6].

4.4. Indications for Surgical Treatment

As there is no definitive, etiologically targeted treatment, all treatments are palliative. The goal of treatment is recovery of function and improved appearance. It is not necessary to place patients at risk by performing premature, radical surgery for this benign disease [3]. Lipectomy is considered the treatment of choice for Madelung's disease, performed primarily in severe cases involving multiple body structures or producing compression symptoms [1]. Lipectomy is necessary if there is obstruction of the trachea or pharynx leading to dyspnea, dysphagia, or related symptoms [1]. Lipectomy is also indicated for treating severe deformities and for removal of redundant skin [8]. Liposuction has been used to treat less severe cases with limited areas of involvement or as a second-stage or adjunct treatment. If the lipomas are very diffuse, making them difficult to remove by lipectomy, liposuction should be considered [6]. Liposuction is also more suitable for patients at increased surgical and/or anesthetic risk [3]. Some authors recommend that liposuction not be applied in the submental region or in regions with scars from previous surgery [8]. Grassegger et al. reported the safe use of tumescent liposuction in patients with Madelung's disease and liver cirrhosis. The patients had compensated disease, minor procedures, low total lidocaine doses, and careful postoperative surveillance [7].

4.5. Novel Techniques

Some revisions of standard lipectomy and liposuction treatment have been evaluated in Madelung's patients. In 2003, Constantinidis et al. reported satisfactory outcomes using combined lipectomy and liposuction in 11 cases with masses in the head and neck region [49]. Bassetto et al. described use of ultrasound-assisted liposuction to prevent injury to surrounding structures, such as blood vessels and nerves [58]. This technique provided gentle, precise liposuction that reduced damage to subcutaneous tissue and vascular structures but had unsatisfactory cosmetic outcomes [3, 58]. With the tunneling technique, most subcutaneous neurovascular plexus remain intact, and the problem of redundant loose skin is also solved [59]. Andou et al. reported a case in which improved lipectomy using a cervical dissection technique was helpful for treating Madelung's collar [11]. Tremp et al. found that tightening of the skin achieved by power-assisted liposuction improved cosmetic outcomes and was an effective method [60]. Pinto et al. proposed a rhytidectomy approach for recurrent Madelung's disease [61] using multiple-stage surgery. A small submental incision and slightly modified rhytidectomy incisions were made to access the anterior and lateral neck during the supine stage. A posterior neck incision was then made during the prone stage to optimize skin redraping and address the posterior neck hump [34]. Pinto et al. [61] used an inverted T shaped incision (sagittal and suprasternal incisions) successfully, which offers good exposure and allows for removal of skin excesses.

5. Conclusion

The most effective treatments of Madelung's disease were lipectomy and liposuction, both of which have advantages and drawbacks. Before surgery, patients should be informed of the risks and benefits of lipectomy and liposuction and be made aware of the risk of lipoma recurrence. The choice of surgical procedure depends on the disease extent, patient expectations, and the surgeon's experience. This systematic review included a relatively small number of cases. Some clinical data was missing, and some reports were of rare cases that were not truly representative. Despite these limitations, the examples of successful treatment of Madelung's disease provide alternatives for managing patients. Future trends in treatment of Madelung's disease would benefit from study of its etiology and pathogenesis. Experience with modified techniques of liposuction or lipectomy should be expected to make treatment more effective.
  57 in total

1.  Madelung syndrome (benign lipomatosis): clinical course and treatment.

Authors:  Vedran Uglesić; Predrag Knezević; Morena Milić; Davor Jokić; Damir Kosutić
Journal:  Scand J Plast Reconstr Surg Hand Surg       Date:  2004

2.  Histomorphometry of dystrophic fat in a patient suffering Madelung's disease.

Authors:  Tommaso Agostini; Raffaella Perello; Daniele Bani; Andrea Mori; Alessandro Quattrini Li; Giulia Lo Russo
Journal:  J Plast Reconstr Aesthet Surg       Date:  2013-08-02       Impact factor: 2.740

3.  Images in clinical medicine. Symmetric lipomatosis of the tongue.

Authors:  Ju Wan Kang; Jeong Hong Kim
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

4.  Facelift in a patient with benign symmetric lipomatosis and HIV facial lipoatrophy: a case report.

Authors:  Zena Pinnella; John Pinnella
Journal:  Ann Plast Surg       Date:  2014-09       Impact factor: 1.539

5.  Laryngeal involvement in Madelung's disease with acute airway compromise.

Authors:  Chia-Hsuan Lee; Kun-Tai Kang; Jenq-Yuh Ko; Wei-Hsiu Chang
Journal:  Kaohsiung J Med Sci       Date:  2012-04-22       Impact factor: 2.744

6.  Madelung syndrome with pubic involvement.

Authors:  Onder Tan; Duygu Ergen
Journal:  Dermatol Surg       Date:  2008-03-24       Impact factor: 3.398

7.  Osteoporosis, weight gain and atypical fat accumulations - a typical feature not only for Cushing's, but also Madelung's disease: A case report.

Authors:  Claudia Friedl; Eva Sampl; Eva-Christina Prandl; Doris Wagner; Jutta C Piswanger-Soelkner; Alexander R Rosenkranz; Astrid Fahrleitner-Pammer
Journal:  Wien Klin Wochenschr       Date:  2011-09-15       Impact factor: 1.704

8.  Dysphagia and obstructive sleep apnoea in Madelung's disease.

Authors:  S Ali; A Kishore
Journal:  J Laryngol Otol       Date:  2006-12-13       Impact factor: 1.469

9.  An Unusual Case of Madelung's Disease with Multiple Atypical Fractures.

Authors:  Abdurrahman Tufan; Ridvan Mercan; Arif Kaya; Mehmet Engin Tezcan; Berivan Bitik; Mehmet Akif Ozturk; Seminur Haznedaroğlu; Berna Goker
Journal:  Case Rep Orthop       Date:  2012-12-31

10.  Syndrome in question.

Authors:  Cínthia Rosane Orasmo; Juliana Polizel Ocanha; Silvia Regina Catharino Barraviera; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

View more
  7 in total

1.  Madelung disease in a 58-year-old man.

Authors:  Shigehiro Karashima; Takashi Yoneda
Journal:  CMAJ       Date:  2019-01-14       Impact factor: 8.262

2.  Cbl Proto-Oncogene B (CBLB) c.197A>T Mutation Induces Mild Metabolic Dysfunction in Partial Type I Multiple Symmetric Lipomatosis (MSL).

Authors:  Ke Chen; Xinxing Wan; Liling Zhao; Shaoli Zhao; Lin Peng; Wenjun Yang; Jingjing Yuan; Liyong Zhu; Zhaohui Mo
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-06       Impact factor: 3.168

3.  Madelung's disease - progressive, excessive, and symmetrical deposition of adipose tissue in the subcutaneous layer: case report and literature review.

Authors:  Monika Szewc; Robert Sitarz; Nina Moroz; Ryszard Maciejewski; Ryszard Wierzbicki
Journal:  Diabetes Metab Syndr Obes       Date:  2018-11-26       Impact factor: 3.168

4.  Diagnostic and surgical challenges of progressive neck and upper back painless masses in Madelung's disease: A case report and review of literature.

Authors:  Ya-Jie Yan; Shi-Qing Zhou; Chun-Qiao Li; Yan Ruan
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

5.  Madelung's Disease as an Example of a Metabolic Disease Associated with Alcohol Abuse-Diagnostic Importance of Computed Tomography.

Authors:  Przemysław Jaźwiec; Maria Pawłowska; Karolina Czerwińska; Małgorzata Poręba; Paweł Gać; Rafał Poręba
Journal:  Int J Environ Res Public Health       Date:  2022-04-24       Impact factor: 3.390

6.  Madelung's Disease: Analysis of Clinical Characteristics, Fatty Mass Distribution, Comorbidities and Treatment of 54 Patients in China.

Authors:  Runze Li; Chuanxiao Wang; Quandong Bu; Wenshen Pu; Bin Zhou; Lin Che; Hui Zhang; Yan Xu; Hong Luan
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-06       Impact factor: 3.249

7.  Madelung's disease in a non-alcoholic Ethiopian male patient mistaken for obesity: a case report.

Authors:  Yared Zenebe Zewde
Journal:  BMC Endocr Disord       Date:  2021-07-03       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.